Cargando…

Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre

OBJECTIVE: Cancer-associated venous thromboembolism (CAT) is a common disease or complication which is associated with reduced survival and incurring a substantial health-care cost. Low molecular weight heparin (LMWH) remained the gold standard treatment option available. Direct oral anticoagulants...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmat, Azmi Nor Mohd Farez, Wan Puteh, Sharifa Ezat, Yusak, Suhana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068192/
https://www.ncbi.nlm.nih.gov/pubmed/34837918
http://dx.doi.org/10.31557/APJCP.2021.22.11.3601
_version_ 1784700174069661696
author Ahmat, Azmi Nor Mohd Farez
Wan Puteh, Sharifa Ezat
Yusak, Suhana
author_facet Ahmat, Azmi Nor Mohd Farez
Wan Puteh, Sharifa Ezat
Yusak, Suhana
author_sort Ahmat, Azmi Nor Mohd Farez
collection PubMed
description OBJECTIVE: Cancer-associated venous thromboembolism (CAT) is a common disease or complication which is associated with reduced survival and incurring a substantial health-care cost. Low molecular weight heparin (LMWH) remained the gold standard treatment option available. Direct oral anticoagulants (DOACs) have recently become more popular in the guidelines, they are still few and inconsistent across the current literature. The aim of this study was to evaluate rivaroxaban in treatment of CAT. METHODS: In this prospective real-world study, we recruited and followed up patients diagnosed with CAT treated with rivaroxaban or standard of care as a control for 12 months or until death. Baseline characteristics were collected at the study entry. The primary outcomes were recurrent DVT or PE and death within 12 months after treatment initiation. Safety outcomes were composite outcomes of major and minor bleeding. RESULTS: A total of 80 patients confirm CAT with radiological imaging were recruited; 39 patients were evaluated in the control arm and 41 patients in the rivaroxaban arm. The 12 months cumulative CAT recurrence rate was 46.2% in control and 39% in rivaroxaban (p=0.519). The 12-month death was not a statistically significant difference between both arms (20.5% vs. 31.7%, p=0.255). The cumulative rate of composite safety outcomes was similar in both groups (17.9% vs. 12.2%, p=0.471). CONCLUSION: The result of this small but important real-world evidence proofs that rivaroxaban is an effective and safe alternative to the standard of care for CAT in Malaysia’s cancer population.
format Online
Article
Text
id pubmed-9068192
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-90681922022-05-06 Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre Ahmat, Azmi Nor Mohd Farez Wan Puteh, Sharifa Ezat Yusak, Suhana Asian Pac J Cancer Prev Research Article OBJECTIVE: Cancer-associated venous thromboembolism (CAT) is a common disease or complication which is associated with reduced survival and incurring a substantial health-care cost. Low molecular weight heparin (LMWH) remained the gold standard treatment option available. Direct oral anticoagulants (DOACs) have recently become more popular in the guidelines, they are still few and inconsistent across the current literature. The aim of this study was to evaluate rivaroxaban in treatment of CAT. METHODS: In this prospective real-world study, we recruited and followed up patients diagnosed with CAT treated with rivaroxaban or standard of care as a control for 12 months or until death. Baseline characteristics were collected at the study entry. The primary outcomes were recurrent DVT or PE and death within 12 months after treatment initiation. Safety outcomes were composite outcomes of major and minor bleeding. RESULTS: A total of 80 patients confirm CAT with radiological imaging were recruited; 39 patients were evaluated in the control arm and 41 patients in the rivaroxaban arm. The 12 months cumulative CAT recurrence rate was 46.2% in control and 39% in rivaroxaban (p=0.519). The 12-month death was not a statistically significant difference between both arms (20.5% vs. 31.7%, p=0.255). The cumulative rate of composite safety outcomes was similar in both groups (17.9% vs. 12.2%, p=0.471). CONCLUSION: The result of this small but important real-world evidence proofs that rivaroxaban is an effective and safe alternative to the standard of care for CAT in Malaysia’s cancer population. West Asia Organization for Cancer Prevention 2021-11 /pmc/articles/PMC9068192/ /pubmed/34837918 http://dx.doi.org/10.31557/APJCP.2021.22.11.3601 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ahmat, Azmi Nor Mohd Farez
Wan Puteh, Sharifa Ezat
Yusak, Suhana
Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre
title Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre
title_full Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre
title_fullStr Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre
title_full_unstemmed Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre
title_short Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre
title_sort efficacy of rivaroxaban use in solid tumour malignancy: experience from a tertiary care cancer centre
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068192/
https://www.ncbi.nlm.nih.gov/pubmed/34837918
http://dx.doi.org/10.31557/APJCP.2021.22.11.3601
work_keys_str_mv AT ahmatazminormohdfarez efficacyofrivaroxabanuseinsolidtumourmalignancyexperiencefromatertiarycarecancercentre
AT wanputehsharifaezat efficacyofrivaroxabanuseinsolidtumourmalignancyexperiencefromatertiarycarecancercentre
AT yusaksuhana efficacyofrivaroxabanuseinsolidtumourmalignancyexperiencefromatertiarycarecancercentre